Skip to main content

Month: April 2024

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year ended December 31, 2023. Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects. Our nearly 100% year-over-year revenue growth in 2023 was primarily driven by our branded products and contract manufacturing. Over the course of the year and into our current first quarter, we have significantly expanded our operational infrastructure, solidified several key strategic partnerships with multi-billion-dollar corporations and made key strategic investments, that collectively...

Continue reading

Medigus Reaps Success with First Installation of a Wireless Charging System for Automatic Car Parks

Tel Aviv, Israel, April 01, 2024 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology-based company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, is excited to announce a landmark achievement by its subsidiary, Charging Robotics Ltd. Which has successfully completed the installation of its wireless charging system for an automated parking system (APS). To the best of Charging Robotics’ knowledge, this is the first installation of a wireless charging system for automatic car parks. Charging Robotics Ltd. (“Charging Robotics”), a subsidiary of Fuel Doctor Holdings, Inc., (“FDOC”) a Delaware corporation listed on the OTC Market (66.84% owned by Medigus) is an innovative wireless charging solutions company for electric vehicles (EVs) The installation, previously...

Continue reading

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission (“SEC”) for the year ended December 31, 2023. The annual report can be accessed on the SEC’s website at www.sec.gov, and on the Company’s website at www.biorestorative.com under “SEC Filing” in the Investors and Media section. 2023 and Recent Pipeline Developments BioRestorative’s two primary platform technologies include: its lead clinical-stage cell therapy candidate, BRTX-100, which consists of 40 million autologous bone marrow-derived, hypoxic-cultured transitional stem cells combined with...

Continue reading

Glucose Health, Inc. Announces Expansion of Fiber Up® Brand – More Drink Mix Flavors and New Fiber Up® Gumdrops

BENTONVILLE, Ark., April 01, 2024 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC: GLUC) is pleased to announce the expansion of its innovative Fiber Up® brand of soluble fiber supplements, just launched in November 2023, with the introduction of two new drink mix flavors plus a new product format of Fiber Up® gumdrops – all to be available for purchase shortly via Amazon. The two new drink mix flavors, Fiber Up® Tropical and Fiber Up® Fruit Punch, are formulated to provide consumers with refreshing and delicious options to support metabolic health with soluble nutrition. These new Fiber Up® flavors combine the clinically benefits of soluble fiber with delicious taste, making it easier for individuals to incorporate fiber into their daily routines. Tropical offers a burst of exotic fruit flavors, while Fruit Punch delivers a classic,...

Continue reading

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates. “Last year was highlighted by the ongoing advancement of our clinical pipeline...

Continue reading

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology ROSELAND, N.J., April 01, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the year ending December 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%. We attribute this performance to the success of our new online sales portal for the STA Single Tooth Anesthesia System® (STA) in the U.S., which has enhanced our margins, while providing us a closer relationship with our dental customers. While this was a transitional...

Continue reading

Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results

TORONTO, April 01, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress:Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior yearCash used in operations for fiscal year 2023 of $12.9 million, down 52% year-over-year, from $27.0 million in the prior year period Cash system revenue for fiscal year 2023 represented approximately 67% of total systems and subscriptions revenue, compared to 58% in the prior year periodMacroeconomic headwinds and accelerated restructuring in international markets resulted in softer-than-expected...

Continue reading

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-1 study in patients with inadequately controlled T2D expected in second quarter of 2024 and anticipated topline data in fourth quarter of 2024 Announced nomination of RJVA-001 as first clinical candidate in the Rejuva® GLP-1 gene therapy platform; completion of IND-enabling studies expected in second half of 2024 Completed initial public offering of common stock raising $110 million in gross proceeds; cash on hand expected to fund operations through 2025 BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) — Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2...

Continue reading

Edible Garden Reports 21.6% Year-over-Year Revenue Growth for 2023

32.8% Year-Over-Year Revenue Growth for Fourth Quarter of 2023 Gross Profit Increases 125.8% in 2023 with Gross Margin Increasing by 270 Basis Points Edible Garden Secures Two New Patents in 2024 Highlighting Company’s Innovation Leadership Position in AgTech; Driving Efficiency and Expected Profitability Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., April 01, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three month and full year periods ended December 31, 2023. Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “We are extremely pleased to report a 21.6%...

Continue reading

Sachem Capital Reports Full Year 2023 Results

Revenues Increase, While Rising Interest Rates and Commercial Real Estate Values Impact Earnings Company to Host Webcast and Conference Call BRANFORD, Conn., April 01, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the year ended December 31, 2023. The Company will host a conference call on Monday, April 1, 2024 at 8:00 a.m. Eastern Time to discuss its financial and operating results. John Villano, CPA, Sachem Capital’s Chief Executive Officer commented, “While we remained disciplined and focused as we grew 2023 revenue nearly 26% over the prior year, we were met with a difficult macroeconomic backdrop including rising interest rates, weakness in commercial real estate, specifically office, and banking sector challenges. As a result, changes in the values of certain commercial...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.